Evaluation of safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels

Trial Profile

Evaluation of safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs Pemafibrate (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Kowa Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 02 Sep 2015 Post-hoc, subgroup analysis results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top